The impact of diabetes mellitus on healthcare costs

. Such an ‘epidemic’ seemed to be con-fined to some high-income countries – mainly the USA – a few years ago, but has now extended to almost all countries in the world. Impaired glucose tolerance and other forms of glucose intolerance are also a major public health prob-lem owing to their association with diabetes incidence and as a cardiovascular risk factor on their own

[1]  C. Weber,et al.  Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspective , 2010, Current medical research and opinion.

[2]  R. Gnavi,et al.  The impact of second‐level specialized care on hospitalization in persons with diabetes: a multilevel population‐based study , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[3]  M. Brito-Sanfiel,et al.  Economic impact of hypoglycemia on healthcare in Spain , 2010, Expert review of pharmacoeconomics & outcomes research.

[4]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[5]  V. Foos,et al.  Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain , 2010, Current medical research and opinion.

[6]  Dario Gregori,et al.  Factors affecting hospitalization costs in Type 2 diabetic patients. , 2009, Journal of diabetes and its complications.

[7]  Sandra L. Tunis,et al.  Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US , 2010, Current medical research and opinion.

[8]  D. Voinovich,et al.  Major complications have an impact on total annual medical cost of diabetes: results of a database analysis. , 2006, Journal of diabetes and its complications.

[9]  Cost impact of self-measurement of blood glucose on complications of type 2 diabetes: the Spanish perspective. , 2009, Diabetes technology & therapeutics.

[10]  J. O'brien,et al.  Direct Medical Costs of Complications Resulting From Type 2 Diabetes in Hie U.S. , 1998, Diabetes Care.

[11]  A. Nicolucci,et al.  The Italian Diabetes and Exercise Study (IDES): design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[12]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[13]  M. Massi-Benedetti The Cost of Diabetes Type II in Europe The CODE-2 Study , 2002, Diabetologia.

[14]  S. Laditka,et al.  Health care use of individuals with diabetes in an employer-based insurance population. , 2001, Archives of internal medicine.

[15]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[16]  F. Chiarelli,et al.  Technology and the issue of cost/benefit in diabetes , 2009, Diabetes/metabolism research and reviews.

[17]  D. Jeffries,et al.  Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy , 2011, The European Journal of Health Economics.

[18]  Jonathan B. Brown,et al.  The progressive cost of complications in type 2 diabetes mellitus. , 1999, Archives of internal medicine.

[19]  B. Schneider,et al.  Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11). , 2007, Swiss medical weekly.

[20]  A. Nicolucci,et al.  Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). , 2010, Archives of internal medicine.

[21]  Simanis Jg Health care expenditures: international comparisons, 1970-80. , 1987 .

[22]  G. Goodall,et al.  Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. , 2010, Swiss medical weekly.

[23]  U. Gerdtham,et al.  Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases , 2010, International journal of environmental research and public health.

[24]  G. Bruno,et al.  The impact of diabetes on prescription drug costs: the population-based Turin study , 2008, Diabetologia.

[25]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[26]  M. Engelgau,et al.  Cost-of-Illness Studies in Diabetes Mellitus , 2012, PharmacoEconomics.

[27]  G. Onder,et al.  Pharmacoeconomics and Aging , 2009, Drugs & aging.

[28]  Ping Zhang,et al.  Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review , 2010, Diabetes Care.

[29]  G. Marchesini,et al.  The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory. , 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[30]  D N Mendelson,et al.  Health care expenditures for people with diabetes mellitus, 1992. , 1994, The Journal of clinical endocrinology and metabolism.

[31]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[32]  M. Magoni,et al.  The evolving burden of HIV infection compared with other chronic diseases in northern Italy * , 2011, HIV medicine.

[33]  S. Bo,et al.  Evaluating hospital costs in type 2 diabetes care: does the choice of the model matter?* , 2006, Current Medical Research and Opinion.

[34]  D. Jeffries,et al.  Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model , 2010, BMC public health.

[35]  A. Amos,et al.  The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.